[Click eStock] "Neopharm, Expecting Growth in Zerode"

Hana Securities analyzed on the 17th that Neopharm will grow centered on Zeroid and Real Barrier.

Park Eun-jung, a researcher at Hana Securities, explained, "Neopharm is estimated to achieve sales of 32.5 billion KRW and operating profit of 7.5 billion KRW on a consolidated basis in the first quarter of this year," adding, "This represents an increase of 15% and 10%, respectively, compared to the same period last year."

She continued, "It is expected to generally meet market expectations," and added, "Operating profit will increase by 10% due to expenses such as advertising and promotional costs."

She forecasted, "The growth rates by Neopharm's brands in the first quarter are expected to be 10% for Atopalm, 40% for Zeroid, and 32% for Real Barrier," and analyzed, "Zeroid will grow through expanding its consumer base by opening stores in Health & Beauty (H&B) channels, and Real Barrier will grow through opening stores in Daiso and expanding offline touchpoints in Japan."

This content was produced with the assistance of AI translation services.